Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma
Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared with usual care.
Related Articles
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Fatty Liver Found in Half of Patients With Type 2 Diabetes, Study Finds
Nonalcoholic fatty liver disease (NAFLD) was linked to elevated liver enzymes in type 2 diabetes mellitus (T2DM) in a recent study, urging early detection and…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Burnout in Hematology Reaches Critical Levels Amid Emotional Strain, Long Hours: Adela Perolla, MD, PhD
Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
AI-Based Tool for Classifying Acute Leukemia Subtypes Shows Promise in Global Study: Merlin Engelke, MS
An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations
Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
ADVANCE Trial Supports DKRd as New Standard of Care for Newly Diagnosed Multiple Myeloma: Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.